HC Wainwright Weighs in on Immunocore FY2030 Earnings

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Immunocore in a research report issued on Wednesday, February 4th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $11.26 for the year. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

IMCR has been the subject of a number of other research reports. Wells Fargo & Company assumed coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 target price for the company. UBS Group set a $55.00 price objective on Immunocore and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Morgan Stanley upped their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

Immunocore Price Performance

Immunocore stock opened at $30.92 on Thursday. The firm has a market capitalization of $1.56 billion, a PE ratio of -54.25 and a beta of 0.78. Immunocore has a 52 week low of $23.15 and a 52 week high of $40.71. The firm’s 50-day simple moving average is $34.92 and its 200 day simple moving average is $34.45. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.Immunocore’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.17 earnings per share.

Institutional Investors Weigh In On Immunocore

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares during the last quarter. DNB Asset Management AS grew its holdings in Immunocore by 6.4% in the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock valued at $295,000 after buying an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares during the last quarter. R Squared Ltd lifted its holdings in shares of Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after acquiring an additional 606 shares during the period. Finally, Virtus Investment Advisers LLC boosted its position in shares of Immunocore by 5.3% in the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company’s stock worth $391,000 after acquiring an additional 625 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.